8-K ·Filed Jun 4, 2026

IQV

IQVIA HOLDINGS INC.
NEUTRAL
Impact 3/10
Horizondays Processed3mo ago SEC0001193125-26-257730
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

This is a liability management transaction with no impact on equity or operations. Monitor upcoming earnings for any change in leverage targets or interest expense guidance, but no immediate trading action warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
IQV ▲ +41.93% at T+60d
NEUTRAL call ✓ call won +41.93% · α vs SPY +37.93% · entry $183.45 → $260.37
Entry anchored
Jun 4, 03:59 PM ET
via exchange tick
T+1d
+0.13%
call +0.13% · α -0.10%
$183.69
settled 4mo ago
T+5d
-1.08%
call -1.08% · α -1.65%
$181.46
settled 4mo ago
T+20d
+12.28%
call +12.28% · α +10.41%
$205.97
settled 3mo ago
T+60d
+41.93%
call +41.93% · α +37.93%
$260.37
settled 5w ago

Price Chart

Loading chart...

Executive Summary

IQVIA's subsidiary priced €950M in senior notes due 2033 at 4.625% to refinance existing debt. This is a routine refinancing of existing indebtedness with no material change to the company's capital structure or credit profile.

Key Facts

  • IQVIA Inc. priced €950M aggregate principal amount of senior notes due 2033 at 4.625% per annum
  • Proceeds will be used to refinance certain existing indebtedness and pay fees/expenses
  • Notes mature June 15, 2033, interest paid semi-annually starting December 15, 2026
  • Closing expected on or about June 11, 2026, subject to customary conditions
  • Offering is a private placement under Rule 144A/Regulation S, not registered under Securities Act

Financial Impact

€950M debt refinancing at 4.625% — no net new capital raised, existing debt replaced

debt

Risk Factors

  • Higher absolute debt level if refinanced debt had lower coupon or shorter maturity
  • Customary closing conditions could delay or prevent the offering

Market Snapshot

Exchange
NYSE
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
80% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-257730
Document: d107340dex991.htm0001193125-26-257730
Document: 0001193125-26-257730-index-headers.html0001193125-26-257730
Document: 0001193125-26-257730-index.html0001193125-26-257730
Document: 0001193125-26-257730.txt0001193125-26-257730
9 reports for IQV
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IQV — sortable, filterable
TypeNow
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 4/10
$236.05 $263.84▲ +11.77%▲ +12.37%$258.21 (+9.39%)
Jul 31, 2026
9w ago
Insider Cluster
NEUTRAL ★ 2/10
$233.36 $260.37▲ +11.57%▲ +10.33%$258.21 (+10.65%)
Jul 28, 2026
9w ago
8-K
BULLISH ★ 7/10
$242.94 $259.42▲ +6.78%▲ +3.40%$258.21 (+6.29%)
Jun 11, 2026
16w ago
8-K
NEUTRAL ★ 3/10
$181.46 $207.85▲ +14.54%▲ +12.76%$258.21 (+42.30%)
Jun 4, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$183.45 $205.97▲ +12.28%▲ +10.41%$258.21 (+40.75%)
Jun 3, 2026
17w ago
8-K
NEUTRAL ★ 3/10
$186.85 $207.04▲ +10.81%▲ +12.43%$258.21 (+38.19%)
Mar 30, 2026
26w ago
Court Ruling
NEUTRAL ★ 1/10
$166.16 $158.98▼ −4.32%▼ −16.94%$258.21 (+55.40%)
Mar 17, 2026
28w ago
Court Ruling
BULLISH ★ 6/10
$168.43 $178.10▲ +5.74%▲ +1.40%$258.21 (+53.30%)
Feb 27, 2026
30w ago
DEFA14A
NEUTRAL ★ 3/10
$174.24 $166.02▼ −4.72%▲ +3.22%$258.21 (+48.20%)
Showing 9 of 9

US Market Status

Market Closed — Opens Mon (64h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access